[go: up one dir, main page]

MX2017013103A - Metodos para el tratamiento de trastornos cardiovasculares. - Google Patents

Metodos para el tratamiento de trastornos cardiovasculares.

Info

Publication number
MX2017013103A
MX2017013103A MX2017013103A MX2017013103A MX2017013103A MX 2017013103 A MX2017013103 A MX 2017013103A MX 2017013103 A MX2017013103 A MX 2017013103A MX 2017013103 A MX2017013103 A MX 2017013103A MX 2017013103 A MX2017013103 A MX 2017013103A
Authority
MX
Mexico
Prior art keywords
treatment
cardiovascular disorders
methods
formula
solvate
Prior art date
Application number
MX2017013103A
Other languages
English (en)
Other versions
MX386902B (es
Inventor
Tom Bert Paul Wigerinck Piet
Albert Eleutherius Van 't Klooster Gerben
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1506228.4A external-priority patent/GB201506228D0/en
Priority claimed from GBGB1507109.5A external-priority patent/GB201507109D0/en
Priority claimed from GBGB1513344.0A external-priority patent/GB201513344D0/en
Priority claimed from GBGB1513991.8A external-priority patent/GB201513991D0/en
Priority claimed from GBGB1521542.9A external-priority patent/GB201521542D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2017013103A publication Critical patent/MX2017013103A/es
Publication of MX386902B publication Critical patent/MX386902B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe compuestos de acuerdo con la fórmula (I): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, o un solvato o la sal de un solvato del mismo, composiciones farmacéuticas que comprenden al mismo, y métodos de tratamiento utilizando el mismo, para usarse en la profilaxis y/o el tratamiento de trastornos cardiovasculares y/o dislipidemia, al administrar el compuesto de acuerdo con la fórmula (I).
MX2017013103A 2015-04-13 2016-03-31 Metodos para el tratamiento de trastornos cardiovasculares. MX386902B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1506228.4A GB201506228D0 (en) 2015-04-13 2015-04-13 Methods For The Treatment Of Cardivascular Disorders
GBGB1507109.5A GB201507109D0 (en) 2015-04-27 2015-04-27 Methods for the treatment of cardiovascular disorders
GBGB1513344.0A GB201513344D0 (en) 2015-07-29 2015-07-29 Methods for the treatment of Cardiovascular disorders
GBGB1513991.8A GB201513991D0 (en) 2015-08-07 2015-08-07 Methods for the treatment of cardiovascular disorders
GBGB1521542.9A GB201521542D0 (en) 2015-12-07 2015-12-07 Methods for the treatment of cardiovascular disorders
PCT/EP2016/057103 WO2016165952A1 (en) 2015-04-13 2016-03-31 Methods for the treatment of cardiovascular disorders

Publications (2)

Publication Number Publication Date
MX2017013103A true MX2017013103A (es) 2018-01-30
MX386902B MX386902B (es) 2025-03-19

Family

ID=55640760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013103A MX386902B (es) 2015-04-13 2016-03-31 Metodos para el tratamiento de trastornos cardiovasculares.

Country Status (18)

Country Link
US (1) US10376520B2 (es)
EP (1) EP3283114B1 (es)
JP (1) JP6898249B2 (es)
KR (1) KR102747428B1 (es)
CN (1) CN107438609B (es)
AU (1) AU2016248727B2 (es)
BR (1) BR112017021589B1 (es)
CA (1) CA2982629C (es)
EA (1) EA037911B1 (es)
ES (1) ES2959612T3 (es)
HR (1) HRP20231192T1 (es)
HU (1) HUE063820T2 (es)
MX (1) MX386902B (es)
PL (1) PL3283114T3 (es)
RS (1) RS64677B1 (es)
SG (1) SG11201708198SA (es)
SM (1) SMT202300328T1 (es)
WO (1) WO2016165952A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2018087202A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
MA37775A1 (fr) 2012-06-22 2017-04-28 Galapagos Nv Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20170141833A1 (en) * 2015-01-23 2017-05-18 Samsung Electronics Co., Ltd. Method and device for supporting data communication in wireless communication system

Also Published As

Publication number Publication date
EA037911B1 (ru) 2021-06-04
HRP20231192T1 (hr) 2024-02-16
US10376520B2 (en) 2019-08-13
EP3283114B1 (en) 2023-09-06
CN107438609B (zh) 2020-10-09
CA2982629A1 (en) 2016-10-20
EA201792265A1 (ru) 2018-04-30
PL3283114T3 (pl) 2024-01-03
JP2018511618A (ja) 2018-04-26
KR102747428B1 (ko) 2024-12-27
KR20170134751A (ko) 2017-12-06
SMT202300328T1 (it) 2023-11-13
JP6898249B2 (ja) 2021-07-07
MX386902B (es) 2025-03-19
BR112017021589A2 (pt) 2018-07-03
CA2982629C (en) 2023-09-05
HUE063820T2 (hu) 2024-02-28
EP3283114C0 (en) 2023-09-06
RS64677B1 (sr) 2023-11-30
SG11201708198SA (en) 2017-11-29
CN107438609A (zh) 2017-12-05
BR112017021589B1 (pt) 2023-05-09
HK1250624A1 (en) 2019-01-11
NZ735883A (en) 2021-11-26
ES2959612T3 (es) 2024-02-27
US20180185377A1 (en) 2018-07-05
EP3283114A1 (en) 2018-02-21
AU2016248727B2 (en) 2021-04-01
WO2016165952A1 (en) 2016-10-20
AU2016248727A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
DOP2019000201A (es) Compuestos inhibidores del vih
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
MX2016017147A (es) Compuestos de indazole substituidos como inhibidores de irak4.
MX2017009449A (es) Inhibidor jak.
AR103680A1 (es) Inhibidores selectivos de bace1
ECSP17038150A (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
UY36124A (es) Derivados de carboxamida
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.